Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
|
Amneal Pharmaceuticals, Inc. (Name of Issuer) |
Class A Common Stock, par value $0.01 (Title of Class of Securities) |
03168L105 (CUSIP Number) |
Christine Krentz 4 Gatehall Drive, Parsippany, NJ, 07054 (908) 409-6700 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
10/03/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 03168L105 |
| 1 |
Name of reporting person
Patel Chintu | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
 (a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
25,910,032.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.2 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
The percentage of ownership of the Class A Common Stock by the Reporting Person presented in this Statement is based on 314,079,309 shares of Class A Common Stock outstanding, as disclosed in the New Issuer's Quarterly Report on Form 10-Q, filed on August 7, 2025.
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Class A Common Stock, par value $0.01 |
| (b) | Name of Issuer:
Amneal Pharmaceuticals, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
400 Crossing Blvd, Bridgewater,
NEW JERSEY
, 08807. |
| Item 4. | Purpose of Transaction |
This Amendment No. 4 to Schedule 13D (this "Amendment No. 4") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 4, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the New Issuer. Capitalized terms used but not defined in this Amendment No. 4 shall have the meanings set forth in the Schedule 13D. On October 3, 2025, the Reporting Person caused a trust controlled by the Reporting Person (the "Trust") to contribute, without consideration, 13,257,287 shares of Class A Common Stock to Shivkan Holdings X, LLC, a Delaware limited liability company ("Shivkan"). The Trust is the sole member of Shivkan. The purpose of these transactions was to facilitate the transactions described in Item 6 below. | |
| Item 5. | Interest in Securities of the Issuer |
| (b) | The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Class A Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 314,079,309 shares of Class A Common Stock outstanding, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed on August 7, 2025: Reporting Person: Chintu Patel Amount beneficially owned: 25,910,032 Percent of class: 8.2% Sole power to vote or to direct the vote: 25,910,032 Shared power to vote or to direct the vote: 0 Sole power to dispose or to direct the disposition: 25,910,032 Shared power to dispose or to direct the disposition: 0 The Reporting Person owns directly (i) 864,033 shares of Class A Common Stock, (ii) 24,977 shares of Class A Common Stock issuable upon exercise of options exercisable for $15.01 per share, which expire on May 7, 2028; (iii) 28,044 shares of Class A Common Stock issuable upon exercise of options exercisable for $14.05 per share, which expire on May 6, 2029; and (iv) 239,726 shares Class A Common Stock issuable upon the vesting and settlement of restricted stock units. The Reporting Person may be deemed to beneficially own 11,495,965 shares of Class A Common Stock held of record by trusts controlled by the Reporting Person and 13,257,287 shares of Class A Common Stock held of record by Shivkan. |
| (c) | The information set forth in Item 4 and Item 6 of this Amendment No. 4 is incorporated by reference herein. |
| (d) | The information set forth in Item 4 and Item 6 of this Amendment No. 4 is incorporated by reference herein. |
| (e) | Not applicable. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
Item 6 of the Schedule 13D is hereby amended and supplemented by adding the following information. On October 3, 2025, Shivkan entered into a Margin Loan Agreement (the "Margin Loan Agreement") with Citibank, N.A. ("Citibank"). In connection therewith, Shivkan agreed to pledge to Citibank 13,257,287 shares of Class A Common Stock (the "Collateral") to secure the obligations of Shivkan under the Margin Loan Agreement, pursuant to a Pledge and Security Agreement, dated as of October 3, 2025, by and between Shivkan and Citibank (the "Security Agreement" and, together with the Margin Loan Agreement, the "Loan Documents"). The obligations of Shivkan under the Margin Loan Agreement mature on April 5, 2027. Upon the occurrence of certain events that are customary with this type of transaction, Citibank may exercise its rights to foreclose on, and dispose of, the Collateral in accordance with the Loan Documents. In order to facilitate the exercise by Citibank of its rights upon the occurrence of any such event, the Issuer also entered into an Issuer Letter Agreement, dated as of October 3, 2025, with Citibank (the "Issuer Agreement"). Copies of the Security Agreement and the Issuer Agreement are attached as Exhibits to this Schedule 13D, and are incorporated herein by reference. Except as set forth herein, the Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies. | |
| Item 7. | Material to be Filed as Exhibits. |
5. Pledge and Security Agreement, dated as of October 3, 2025, by and between Shivkan and Citibank. 6. Issuer Letter Agreement, dated as of October 3, 2025, by and between Shivkan and Citibank. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|